

Progressive Supranuclear Palsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/P559320A6E6BEN.html>

Date: November 2022

Pages: 85

Price: US\$ 2,000.00 (Single User License)

ID: P559320A6E6BEN

Abstracts

Progressive Supranuclear Palsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Progressive Supranuclear Palsy - Drugs In Development, 2022, provides an overview of the Progressive Supranuclear Palsy (Central Nervous System) pipeline landscape.

Progressive supranuclear palsy, also called Steele-Richardson-Olszewski syndrome is a rare neurodegenerative disease that leads to difficulty with balance, movement, vision, speech and swallowing. Symptoms include fatigue, headaches, dizziness, depression, Parkinsonism, behavioral, cognitive, and gait disturbances that cause imbalance and arthralgias. The only proven risk factor for progressive supranuclear palsy is age. Treatment includes anticholinergic medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Progressive Supranuclear Palsy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Progressive Supranuclear Palsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press

releases.

The Progressive Supranuclear Palsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Progressive Supranuclear Palsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 7, 13 and 4 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Progressive Supranuclear Palsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Progressive Supranuclear Palsy (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Progressive Supranuclear Palsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Progressive Supranuclear Palsy (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Progressive Supranuclear Palsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Progressive Supranuclear Palsy (Central Nervous System)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Progressive Supranuclear Palsy (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Progressive Supranuclear Palsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Progressive Supranuclear Palsy - Overview
- Progressive Supranuclear Palsy - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Progressive Supranuclear Palsy - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Progressive Supranuclear Palsy - Companies Involved in Therapeutics Development
- Allyx Therapeutics Inc
- Alterity Therapeutics Ltd
- AlzProtect SAS
- Anhorn Medicines Co Ltd
- Aprinoia Therapeutics Inc
- Arvinas Inc
- Asahi Kasei Pharma Corp
- Asceneuron SA
- AZTherapies Inc
- Cortice Biosciences Inc
- Merck & Co Inc
- NeuroTau Inc
- New Amsterdam Sciences Inc
- Novartis AG
- Pinteon Therapeutics Inc
- ProMIS Neurosciences Inc
- Prothena Corp Plc
- Reata Pharmaceuticals Inc
- Retrotope Inc
- TauC3 Biologics Ltd
- TauRx Therapeutics Ltd
- Transposon Therapeutics Inc

UCB SA

Vaxxinity Inc

Verge Genomics

Voyager Therapeutics Inc

Progressive Supranuclear Palsy - Drug Profiles

AHT-434 - Drug Profile

Product Description

Mechanism Of Action

ALX-002 - Drug Profile

Product Description

Mechanism Of Action

Anti-tau - Drug Profile

Product Description

Mechanism Of Action

Antibodies to Inhibit Tau Protein for Progressive Supranuclear Palsy and Corticobasal

Degeneration - Drug Profile

Product Description

Mechanism Of Action

APNmAb-005 - Drug Profile

Product Description

Mechanism Of Action

ASN-120290 - Drug Profile

Product Description

Mechanism Of Action

AZP-2006 - Drug Profile

Product Description

Mechanism Of Action

bepranemab - Drug Profile

Product Description

Mechanism Of Action

censavudine - Drug Profile

Product Description

Mechanism Of Action

deulinoleate ethyl - Drug Profile

Product Description

Mechanism Of Action

fasudil - Drug Profile

Product Description

Mechanism Of Action

Gene Modified Cell Therapy for Progressive Supranuclear Palsy - Drug Profile

Product Description

Mechanism Of Action

hydromethylthionine mesylate - Drug Profile

Product Description

Mechanism Of Action

MK-8719 - Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibodies to Inhibit tau Protein for Alzhiemer's Disease and Progressive Supranuclear Palsy - Drug Profile

Product Description

Mechanism Of Action

NAS-114 - Drug Profile

Product Description

Mechanism Of Action

NAS-150 - Drug Profile

Product Description

Mechanism Of Action

NIO-752 - Drug Profile

Product Description

Mechanism Of Action

omaveloxolone - Drug Profile

Product Description

Mechanism Of Action

PNT-001 - Drug Profile

Product Description

Mechanism Of Action

PRX-005 - Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Inhibit Tau for Frontotemporal Lobar Dementia (FTLD), Progressive Supranuclear Palsy and Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Frontotemporal Dementia, Lewy Body Dementia, Progressive Supranuclear Palsy and Schizophrenia - Drug Profile

Product Description

Mechanism Of Action

Tau - Drug Profile

Product Description

Mechanism Of Action

Tau - Drug Profile

Product Description

Mechanism Of Action

Tau Degradator - Drug Profile

Product Description

Mechanism Of Action

Tau Modulator - Drug Profile

Product Description

Mechanism Of Action

TBL-100 - Drug Profile

Product Description

Mechanism Of Action

tolfenamic acid - Drug Profile

Product Description

Mechanism Of Action

TPI-287 - Drug Profile

Product Description

Mechanism Of Action

Various Tauopathies - Drug Profile

Product Description

Mechanism Of Action

Progressive Supranuclear Palsy - Dormant Projects

Progressive Supranuclear Palsy - Discontinued Products

Progressive Supranuclear Palsy - Product Development Milestones

Featured News & Press Releases

Apr 11, 2022: APRINOIA Therapeutics received FDA clearance to initiate APNmAb005 Phase 1 clinical trial

Jan 20, 2022: Alzprotect completes recruitment for phase 2a clinical trial for AZP2006 in progressive supranuclear palsy (PSP)

Nov 19, 2021: Announcement of enrollment of first patient in Phase IIa clinical trial of OBP-601 (Censavudine, TPN-101) in patients with progressive supranuclear palsy (PSP)

Sep 30, 2021: Asceneuron to provide update on O-GlcNAcase Pipeline at upcoming conferences

Aug 11, 2021: Retrotope announces completion of enrollment in phase 2 study of RT001 in patients with progressive supranuclear palsy (PSP)

Jun 30, 2021: Retrotope announces initiation of phase 2 study of RT001 in patients with progressive supranuclear palsy (PSP)

May 12, 2021: Voyager Therapeutics presents new preclinical data showing reduction of pathological Tau with Vectorized Anti-Tau antibody

Feb 18, 2021: Woolsey Pharmaceuticals emerges from stealth mode to announce patients enrolled in two new CNS studies

Jan 28, 2021: Pinteon Therapeutics announces upcoming scientific presentations

Sep 14, 2020: Alzprotect forges ahead with first patients enrolled in Phase 2a study in progressive supranuclear palsy (PSP)

Apr 27, 2020: US FDA allows trial to proceed for Retrotope's RT001 in the treatment of progressive supraNuclear palsy (PSP)

Feb 18, 2020: US FDA grants orphan drug designation for Retrotope's RT001 in the treatment of progressive supraNuclear palsy (PSP)

Oct 17, 2019: Arvinas to Present update on Small Molecule to Inhibit Microtubule Associated Protein Tau for Alzheimer's Disease and Progressive Supranuclear Palsy at the 2nd Targeted Protein Degradation Summit

Sep 25, 2019: UCB presents UCB0107 anti-Tau immunotherapy phase I study results at World Movement Disorders Conference

Sep 18, 2019: Alzprotect gets green light from French Regulator to start phase 2a clinical trial in Progressive Supranuclear Palsy (PSP)

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Progressive Supranuclear Palsy, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Progressive Supranuclear Palsy - Pipeline by Allyx Therapeutics Inc, 2022
Progressive Supranuclear Palsy - Pipeline by Alterity Therapeutics Ltd, 2022
Progressive Supranuclear Palsy - Pipeline by AlzProtect SAS, 2022
Progressive Supranuclear Palsy - Pipeline by Anhorn Medicines Co Ltd, 2022
Progressive Supranuclear Palsy - Pipeline by Aprinoia Therapeutics Inc, 2022
Progressive Supranuclear Palsy - Pipeline by Arvinas Inc, 2022
Progressive Supranuclear Palsy - Pipeline by Asahi Kasei Pharma Corp, 2022
Progressive Supranuclear Palsy - Pipeline by Asceneuron SA, 2022
Progressive Supranuclear Palsy - Pipeline by AZTherapies Inc, 2022
Progressive Supranuclear Palsy - Pipeline by Cortice Biosciences Inc, 2022
Progressive Supranuclear Palsy - Pipeline by Merck & Co Inc, 2022
Progressive Supranuclear Palsy - Pipeline by NeuroTau Inc, 2022
Progressive Supranuclear Palsy - Pipeline by New Amsterdam Sciences Inc, 2022
Progressive Supranuclear Palsy - Pipeline by Novartis AG, 2022
Progressive Supranuclear Palsy - Pipeline by Pinteon Therapeutics Inc, 2022
Progressive Supranuclear Palsy - Pipeline by ProMIS Neurosciences Inc, 2022
Progressive Supranuclear Palsy - Pipeline by Prothena Corp Plc, 2022
Progressive Supranuclear Palsy - Pipeline by Reata Pharmaceuticals Inc, 2022
Progressive Supranuclear Palsy - Pipeline by Retrotope Inc, 2022
Progressive Supranuclear Palsy - Pipeline by TauC3 Biologics Ltd, 2022
Progressive Supranuclear Palsy - Pipeline by TauRx Therapeutics Ltd, 2022
Progressive Supranuclear Palsy - Pipeline by Transposon Therapeutics Inc, 2022
Progressive Supranuclear Palsy - Pipeline by UCB SA, 2022
Progressive Supranuclear Palsy - Pipeline by Vaxxinity Inc, 2022

Progressive Supranuclear Palsy - Pipeline by Verge Genomics, 2022
Progressive Supranuclear Palsy - Pipeline by Voyager Therapeutics Inc, 2022
Progressive Supranuclear Palsy - Dormant Projects, 2022
Progressive Supranuclear Palsy - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Progressive Supranuclear Palsy, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Progressive Supranuclear Palsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/P559320A6E6BEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P559320A6E6BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

